THERAPY DOSSIER · th-244081999417

Tetrandrine

Nutraceutical · Tetrandrine, a bis-benzylisoquinoline alkaloid (calcium-channel blocker); ChEMBL returned the isotetrandrine analog only.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Tetrandrine, a bis-benzylisoquinoline alkaloid (calcium-channel blocker); ChEMBL returned the isotetrandrine analog only.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04308317 ↗PHASE4unknown

Tetrandrine Tablets Adjuvant Treatment With COVID-19

COVID-19

Enrolment: 60 · Results not recorded

NCT05245448 ↗NAunknown

Tetrandrine + Methotrexate vs Methotrexate in Rheumatoid Arthritis

Rheumatoid Arthritis

Enrolment: 240 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32461972 ↗2020Reported benefit

Tetrandrine Attenuated Doxorubicin-Induced Acute Cardiac Injury in Mice.

MouseChemical/toxinC57BL/6JMaleOral50 mg/kg in 0.2 mLStarted one day before doxorubicin injection

Model: Acute cardiac injury induced by a single intraperitoneal injection of doxorubicin 15 mg/kg

Tetrandrine prevented doxorubicin-related whole-body wasting and heart atrophy, lowered markers of cardiac injury, improved cardiac function, and reduced oxidative damage and myocardial apoptosis. It increased Nrf2 expression and activity, and its protection was abolished in Nrf2-deficient mice.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…